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ABSTRACT
Background: Prostate cancer (PCa) is a leading cause of cancer-related death of men worldwide. There is an urgent
need to develop novel biomarkers for PCa prognosis and diagnosis in the post prostate specific antigen era. Long
intergenic noncoding RNAs (lincRNAs) play essential roles in many physiological processes and can serve as
alternative biomarkers for prostate cancer, but there has been no systematic investigation of lincRNAs in PCa yet.
Results: Nine lincRNA co-expression modules were identified from PCa RNA-Seq data. The association between the
principle component of each module and the PCa phenotype was examined by calculating the Pearson’s
correlation coefficients. Three modules (M1, M3, and M5) were found associated with PCa. Two modules (M3 and
M5) were significantly enriched with lincRNAs, and one of them, M3, may be used as a lincRNA module-biomarker
for PCa diagnosis. This module includes seven essential lincRNAs: TCONS_l2_00001418, TCONS_l2_00008237,
TCONS_l2_00011130, TCONS_l2_00013175, TCONS_l2_00022611, TCONS_l2_00022670 and linc-PXN-1. The
clustering analysis and microRNA enrichment analysis further confirmed our findings.
Conclusion: The correlation between lincRNAs and protein-coding genes is helpful for further exploration of
functional mechanisms of lincRNAs in PCa. This study provides some important insights into the roles of lincRNAs
in PCa and suggests a few lincRNAs as candidate biomarkers for PCa diagnosis and prognosis.
Background
Prostate cancer (PCa) is one of the most common types
of cancer and is the second leading cause of cancer
death in American men. The incidence of prostate can-
cer is increasing but varies remarkably among races and
countries [1-4]. It has become fundamentally important
to uncover the underlying mechanisms in prostate
cancer due to the high risk of metastasis. Recent high
throughput technologies, such as whole genome [5] and
whole exome sequencing [6], have helped investigators
to reveal genetic alternations including DNA structural
change in the PCa genome. Epigenetic modification (e.g.
DNA methylation, chromatin acetylation) also contri-
butes to PCa development. For example, hypermethyla-
tion of CpG islands located in gene promoters (e.g.,
E-cadherin, PTEN, and RB) is frequently found in
advanced PCa. Therefore, cancer is now considered to
be a disease of the genome [7].
During the past decade, researchers have primarily
focused on investigating the roles of protein-coding
genes in cancer development. The recently published
ENCODE project unveiled that a large portion (80.4%)
of the human genome participates in at least one bio-
chemical chromatin and/or RNA associated event in
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cells. Only about 2 percent of the genome is translated
into proteins while the remaining is expressed as noncod-
ing RNAs (ncRNAs) [8]. Noncoding RNAs have long been
considered as “junk RNA” or “transcriptional noise.” In
the world of ncRNAs, long non-coding RNAs (lncRNAs)
are defined by the size >200 nt. Recently, it has been
recognized that lncRNAs are a new class of ncRNAs for
its essential roles in controlling every level of gene expres-
sion in various physiological processes, including develop-
ment, differentiation and other biological mechanisms [9].
LncRNAs are considered one of the driving forces during
tumorigenesis [10]. LncRNAs often overlap with or are
interspersed between coding and non-coding transcripts.
From the genetic point of view, lncRNAs can be classified
into five broad categories [11]: (i) sense - when a lncRNA
overlaps one or more exons of another transcript on the
same strand, (ii) antisense - when a lncRNA overlaps one
or more exons of another transcript on the opposite
strand, (iii) bidirectional - when the expression of the
lncRNA and a neighboring coding transcript on the oppo-
site strand is initiated in close genomic proximity, (iv)
intronic - when a lncRNA is derived from an intron of a
second transcript, and (v) intergenic - when a lncRNA lies
as an independent unit within the genomic interval
between two genes. In this study, we used the RNA-Seq
data of matched normal and tumor samples of PCa for
studying the functions of long intergenic non-coding
RNAs (lincRNAs). We focused on the co-expression
between coding genes and lincRNAs to investigate the
role of lincRNAs and to identify the putative lincRNA
module biomarkers in prostate cancer, the PCa biomarker
identification is becoming very essential in the era of post
prostate specific antigen [12,13].
Methods
Datasets
RNA-Seq data were downloaded from the National Center
for Biotechnology Information (NCBI) Sequence Read
Archive (SRA) [14] database with accession number
SRP002628. This data includes the sequenced transcrip-
tome (polyA+) of 20 prostate cancer tumors and 10
matched normal tissues using Illumina GAII platform.
Bowtie2 index of the human genome (hg19) is retrieved
from Bowtie2 [15] software website. The latest human
Ensemble [16] annotation file (GRCh37) was downloaded
from the Ensemble website. We obtained Gene Transfer
Format (GTF) GENCODE Genes V17 Track file and
lincRNA Transcripts Tracks file from the University of
California Santa Cruz (UCSC) [17] Genome Browser
Tables.
Data preprocessing
We first used NCBI SRA toolkits from the NCBI website
to transfer the sample data format from SRA to FASTQ.
We used FastQC tool for checking quality of the sequen-
cing data. Then, we wrote a Perl script to combine
mRNA-lincRNA gene annotation files from UCSC Table
Browser [17]. We removed the annotation that contained
“exon,” because the exonic structure is usually identified
from the genomic alignment of the transcript sequence
other than the protein sequence. Exons were numbered
according to their positions within the mRNA sequence.
“Exon” refers to transcription and “CDS” to translation, so
we removed the exons and added lincRNA GTF files into
a final file “hg19.mRNA.lincRNA.gtf” for TopHat map-
ping. We selected the gene names and Ensemble numbers
which correspond to the gene names from the latest
version of human Ensemble annotation file (GRCh37).
Finally the corresponding relations of the two features
were summarized in table “Gene-Ensemble” (Additional
file 1 - Table S1) for conversion between gene symbol and
EMSEMBL_gene_ID.
Pipeline for exploring lincRNA’s functions in PCa
We explored the lincRNAs functions in the following
3 steps using RNA-Seq data. The detailed pipeline for
data proves, differential gene expression and functional
analyses is described in Figure 1.
Mapping, assembly and gene expression calculation
We used a de novo strategy to assemble the 30 samples
and reconstruct the transcriptome. We used the TopHat
2.0.9 and Cufflinks 2.1.1 [18] for mapping and transcript
assembly. Cufflinks adds the parameter “-G” in the step
of assembly. We used the “hg19.mRNA.lincRNA.gtf” as
GTF file and used it as a “reference” annotation.
Composite genes expression matrixes
We calculated the gene expression level only when the
short reads could map to a gene. Expected fragments per
1000 base of transcript per million fragments mapped
(FPKM) [19], has been typically used to measure genes
expression level from RNA-Seq data. We wrote a Perl
script to merge gene expression files from the 30 samples
into a 30*116457 matrix file named “hg19.mRNA.lincR-
NAexprssion”. Here, expression of each of those genes
was calculated by Cufflinks. The first column of the
matrix is the Ensemble number. Given that one gene
may generate multiple transcripts due to alternative spli-
cing, we removed the decimal points in the Ensemble
numbers and chose the maximum FPKM value to repre-
sent the gene expression. Then, we mapped the Ensemble
numbers to official gene names using “Gene-Ensemble”
file. We finally obtained genes and lincRNA expression
level in the whole set of tumor samples and the whole set
of matched normal tissue samples, respectively.
Processing mRNAs and lincRNAs expression matrices
The expression matrix files were processed in the fol-
lowing four steps.
(1) Genes with null expression value in all 30 samples
were removed.
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Figure 1 Analysis pipeline for discovery and characterization of prostate cancer associated lincRNA modules and biomarkers. (A) RNA-Seq
data processing. (B) Differential expression analysis. (C) Functional analysis.
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(2) The non-zero minimum value of gene expression (the
threshold set to 0.001) was assigned to replace zero values
in the same line. For those genes that were not expressed
in a sample, we assigned them the minimum value of the
expression observed in other samples. The rationale is that
these non-zero values represent minimum expression
levels of genes and the transcripts are tissue-specific and
under dynamic change, even though the expression level is
very low. We did not remove the genes with zero expres-
sion values because they may represent weak signals.
(3) The rows with more than ten low expression genes
(expression FPKM value < 0.05) were deleted.
(4) Finally, the expression matrix data was transformed
by log2. The log2 transformation makes data convenient
for gene expression comparison, as typically applied in
gene expression studies.
Differential expression analysis (mRNAs and lincRNAs)
We used Cuffdiff [18] software to calculate the differential
expression (DE) between tumor and tissue samples. First,
we transformed the Ensemble number in the DE profile to
the gene name based on the “gene-ensemble” file. For the
same transcription, we chose the one with a smaller log2
fold-change value. P-values were calculated to evaluate the
statistical significance of the differential expression and
the cutoff was set as 0.05. The top 5000 differentially
expressed genes were selected for further analysis (Addi-
tional file 2 - Table S2).
Network construction and module detection based on the
differentially expressed genes
The network approach allows us to explore a set of
interacting genes measured by modules or sub-
networks that are involved in a complex disease like
PCa. Gene co-expression analysis attempts to study the
combined effects by identifying group of genes that are
concordantly expressed, which may unveil the underly-
ing molecular mechanisms of a disease [20]. For
instance, Horvath and colleagues have developed a widely
used algorithm WGCNA (weighted gene co-expression
network analysis) [21] to search for co-expression mod-
ules. The R package WGCNA implements a suite of tools
for network construction. The initial co-expression net-
work based on Pearson’s correlation coefficients may not
be a scale-free network. In order to construct a scale-free
network and identify important modules, we used a
weighted adjacency matrix implemented in WGCNA.
A step-by-step network construction and module detec-
tion method was used in our study. A selected power
(power = 7) was determined through a soft-threshold
approach implemented in WGCNA. With the constructed
network, we then clustered the highly co-expressed genes
into 9 co-expression modules (M1-M9). The clustering
could be visualized in Figure 2, with each clustered mod-
ule having a different color. The list of lincRNAs in each
module is provided in Table 1.
Figure 2 Network construction and module identification.
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Enrichment analysis of co-expression genes and
identification of transcription factors or microRNAs
associated with the modules
We performed canonical pathway analysis and Gene
Ontology (GO) [22] analysis of the co-expression genes
in the modules, both of which are commonly used in
gene set enrichment analysis for understanding the func-
tions of a set of genes. An integrated software suite,
MetaCore™, was used for mapping the co-expression
genes in the modules to functional categories. Signifi-
cantly enriched pathways (p-value <0.01) from the Meta-
Core™ database were retrieved. For the 9 candidate
modules, we recalculated the Module Membership
(KME) of each gene by its correlation with module eigen-
genes. The online tool WebGestalt [23] was used to iden-
tify the module associated TFs and miRNAs. The
identification is based on the enrichment and association
analysis of miRNAs/TFs and their targeted genes [24].
Results and discussion
Overview of lincRNAs-mRNAs differential expression
As we described in the Methods section, we used RNA-
Seq data from 20 PCa samples and 10 matched control
samples to identify differentially expressed lincRNAs in
PCa. The top 5000 differential raw expression files con-
tained 209 lincRNAs and 4791 protein-coding genes.
These 209 lincRNAs were mapped to the catalog of the
Human Body Map lincRNAs [25] and 94 of them had
corresponding transcript_id in the latest version of the
annotation file. The list of these lncRNAs was provided
in Additional file 3 - Table S3.
Identification and characterization of PCa-associated
co-expression modules
Co-expression modules were defined by a robust dynamic
hierarchical tree and sets of tightly co-regulated genes
with the measurement of dissimilarity (i.e. 1-topological
overlap matrix) [26]. We set the minimum module size to
30 to ensure a qualified number of genes for the further
analysis. The adjacent modules were merged based on
the parameter of cutHeight. Modules with a minimum
cutHeight 0.25 were merged. Principle component ana-
lysis (PCA) of the expression matrix for each module
was performed. We denoted the first principal compo-
nent (PC) as the module eigengenes and used it to
represent the overall expression profile of the module
[27]. We investigated the association between the PC
of each module and the PCa phenotype by calculating
Pearson’s correlation coefficients. The p-value cutoff
for the relationship was set to be 0.03. Three modules,
M3 (p value = 0.028), M5 (p value = 1.49 × 10-3) and
M1 (p value = 8.22 × 10-3) were found to be potential
risk-related modules.
The clustering analysis showed that the eigengenes of
module M3 and module M5 are close to each other (M3:
MEcyan, M5: MEmagenta in Figure 3). In addition, the
eigengenes of these two modules are rich in lincRNAs and
regulated by the same transcription factor Sp1 (Specificity
protein 1) (see Figure 4), confirming the regulatory role of
lincRNA in prostate cancer.
For each module gene, the KME value was calculated
based on the correlation between the gene expression and
the module eigengenes. The genes having the top 50 kME
values in each module were used for the further analysis.
These genes were provided in Additional file 4 - Table S4.
Eight of the nine modules were found significantly
enriched with transcription factor and microRNA tar-
gets. Among them, three transcription factors, Sp1, SRF
(serum response factor) and ETS2 (v-ets avian erythro-
blastosis virus E26 oncogene homolog 2) (Figure 4), and
seven microRNAs, miR-200b, miR-15a, miR-24, miR-
330, miR-17-5p, miR-155 and miR-101, are particular
interesting because of the following two reasons. First,
the value of adjP is smaller than 0.05 during the enrich
process, which means that they have statistical signifi-
cance. Second, these seven microRNAs have been
reported to have potential regulatory roles in PCa
(details in Additional file 5 - Table S5).
Table 1. Summary of 9 co-expression network modules
Module # DE-PCGs* # DE-lincRNAs* Total genes lincRNAs (%)
M1(Black) 630 23 653 3.50
M2(Blue) 1658 48 1706 2.80
M3(Cyan) 167 17 184 9.20
M4(Light cyan) 55 0 55 0
M5(Magenta) 740 84 824 10.19
M6(Midnight blue) 72 0 72 0
M7(Pink) 164 1 165 0.60
M8(Purple) 200 2 202 0.99
M9(Turquoise) 1105 34 1139 2.99
All in 9 modules 4791 209 5000 0.0418
*# DE-PCGs/lincRNAs: number of differentially expressed protein-coding genes or lincRNAs
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An indirect mechanism of androgen action has recently
been identified in which Serum Response Factor (SRF)
mediates the effects of AR (androgen receptor) on pros-
tate cancer cells. Androgen-responsive SRF target genes
affect the progression of PCa cell behavior by modulating
cell migration, which may have implications for thera-
peutic intervention downstream of AR and SRF [28].
Likewise, the ETS2 was reported to be associated with
PCa too. The presence of ETS2 is positively correlated
with a more transformed phenotype and blockage of
ETS2 function reduces transformed properties of pros-
tate cancer cells [29]. Sp1 is an important transcription
factor in various cellular processes and has been shown
to be related to many types of tumorigenesis including
prostate cancer [13,30]. Sp1 activates genes by binding to
GC/GT-box sequences present within the gene’s promo-
ter region [31]. This activation leads to two glutamine-
rich trans-activation domains which directly associate
with the TATA-binding protein and the TBP-associated
factor 4 [32]. Sp1 directly binds to histone acetyltrans-
ferase (CBP/p300) and recruits the ATP-dependent
chromatin remodeling complex (SWI/SNF) [33,34].
According to the related study, Sp1 regulates key genes
associated with PCa including androgen receptor (AR),
c-Met, FAS, MMP, FLIP and TGF-b. It is clear that Sp1
plays an important role in the development of PCa, and
our finding based on lincRNA module analysis sug-
gested the Sp1 role may be acted through lncRNA too.
Interestingly, these modules are also enriched with
microRNAs that are directly involved in the occurrence
and progress of cancer. We conducted a literature survey
and summarized a list of the reported microRNA-based
biomarkers in PCa. Some of the module-enriched micro-
RNAs are well-known biomarkers fro the PCa. For
instance, miR-200B is a downstream target of androgen
receptor which links its expression to decreased tumori-
genicity and metastatic capacity of the prostate cancer
cells [35]. Recent research shows that miR-24 could be an
Figure 3 Module eigengenes cluster analysis. (A). Multi-dimensional scaling plots of the genes in the nine modules (M1: Black, M2: Blue, M3:
Cyan, M4: Light cyan, M5: Magenta, M6: Midnight blue, M7: Pink, M8: Purple, M9: Turquoise). (B) Eigengene dendrogram.
Figure 4 Transcription Factor Enrichment analysis. Sp1 was identified as an important regulator in 4 PCa associated co-expression modules.
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effective drug target for treatment of hormone-insensitive
prostate cancer or other types of cancers [36]. miR-330
acts as an anti-metastatic miRNA in prostate cancer [37]
and putative tumor suppressors. In addition, miR-15a is
homozygously deleted in a subset of prostate cancers, sug-
gesting that miR-15a could be important in the develop-
ment of prostate cancer [38].
Our observation indicated that genes with similar func-
tions within the same modules could contribute risk to
prostate cancer in a co-expression manner. The modules
with different functions can be regulated synergistically by
the same genetic components, e.g. transcription factors
and microRNAs, which play important roles in the devel-
opment of prostate cancer. The enrichment analysis
results of 8 modules revealed significant correlation
between the modules.
The number of lincRNA in M3 and M5 modules is rela-
tively high. Both of these two modules are associated with
prostate cancer according to the p values, and they are
regulated by the same genetic composition as Sp1. These
observations indicated that lincRNAs may play roles as
transcriptional regulators in prostate cancer.
Characterization of lincRNAs in the M3 module
Among the two modules enriched with lincRNAs (M3
and M5), M3 is particularly interesting regarding its asso-
ciation with PCa since it contains lincRNAs with top
kME value (topGeneskME) while M5 module does not.
We plotted the lincRNAs based co-expression module by
its kME values and correlations (Figure 5). It is clear that
this module is enriched with hub lincRNAs. This co-
expression module contains 17 lincRNAs and 4 lincRNAs
in topGeneskMElist; they are: “TCONS_l2_00011130”,
“TCONS_l2_00022611”, “TCONS_l2_00008516”, and
“TCONS_l2_00026666.” According to the catalogue of
the Human Body Map lincRNAs and TUCP transcripts
[25], these four lincRNAs all belong to the TUCP (Tran-
scripts of uncertain coding potential) catalogue. We then
performed the Gene Set Enrichment Analysis (GSEA) of
those genes in module M3. The Gene Ontology analysis
revealed that this module was involved in “viral transcrip-
tion” [39], “translation termination” [40], “viral gene
expression” [41], “SRP-dependent cotranslational protein
targeting to membrane” [42], and “cotranslational protein
targeting to membrane”. Furthermore, the genetic com-
ponents regulate results showed that the M3 module was
enriched with prostate cancer associated transcription
factor Sp1, and Sp1 has been considered as an important
target since it regulates important genes like androgen
receptor (AR), c-Met, prostate specific antigen (PSA) and
transforming growth factor (TGF-b), etc., which are
involved in cell cycle, proliferation, cell differentiation
and apodosis [43].
Five microRNAs were found to be significantly enriched
in the M3 module. They are miR-24, miR-323, miR-518C,
miR-149, and miR-96. miR-24 has been reported to have
its function in prostate cancer development. We con-
ducted the network analysis on the M3 module. We calcu-
lated the degree of the nodes in the M3 module network,
according to the attribute of the network hubs. After filter-
ing the low degree nodes (degree minimum value = 3), we
used Cytoscape [44] for the network visualization. Finally,
7 lincRNAs (TCONS_l2_00022611, TCONS_l2_00008237,
TCONS_l2_00022670, linc-PXN-1, TCONS_l2_00011130,
TCONS_l2_00001418, and TCONS_l2_00013175; listed in
Table 2) in the M3 module are included in this network
for their regulatory function.
In summary, both the enrichment analysis and network
analysis could validate the functional role of lincRNAs in
prostate cancer. The results of enrichment analysis con-
firmed that this lincRNA-based co-expression module,
M3, is biologically important in PCa. The lincRNAs in the
Figure 5 The M3 module is enriched with lincRNA hubs in the co-expression network.
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M3 module might regulate protein-coding genes through
transcription factors and/or microRNAs, and their abnor-
mal changes may lead to prostate cancer development.
Conclusions
Studies using high-throughput data have demonstrated
that lincRNAs play roles in complex diseases including
prostate cancer; however, the specific regulation has largely
been unknown. In this study, we proposed a pipeline for
discovery and characterization of prostate cancer associated
lincRNA modules and biomarkers. A gene co-expression
network was constructed using the whole transcriptome
data that includes both lincRNAs and protein-coding genes.
Through co-expression network analysis, we revealed 9 can-
didate modules that were differentially expressed between
tumors and controls. The enrichment and association ana-
lysis with TF and microRNA highlighted the genetic factors
that regulate the expression of the modules in a synergistic
manner. This study helps to understand the potential func-
tions and regulations of lincRNAs in prostate cancer, and
also facilitates the development of diagnostic and prognostic
tools for prostate cancer. The lncRNA analysis pipeline can
also be applied to other complex disease studies including
other types of cancer. The further experimental validation
of the key TFs, microRNAs and the lincRNA module bio-
markers in PCa will be our next step.
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